HER-2, P53 and hormonal receptors protein expression as predictive factors in breast cancer prognosis

Rose DP, Royak-Schaler R. Tumor biology and prognosis in black breast cancer patients: a review. Cancer Detect Prev 2001; 25: 16–31.

Ikpatt OF, Kuopio T, Collan Y. Proliferation in African breast cancer: biology and prognostication in Nigerian breast cancer material. Mod Pathol 2002; 15: 78.

Simon MS SR. Racial differences in breast cancer survival: the interaction of socio-economic status and tumor biology. Am J Obstet Gynecol 1997; 176: 233–236.

Cheng SH, Tsou MH, Liu MC, et al. Unique features of breast cancer in Taiwan. Breast Cancer Res Treat 2000; 63: 213–223.

Chow LW TA, Cheung KL, Au GK, et al. Current status of breast cancer in Hong Kong. Chin Med J (Engl) 1997; 110: 474–478.

Ezzat A RM, Zwaan F, Brigden M, et al. The lack of age as a significant prognostic factor in non-metastatic breast cancer. Eur J Surg Oncol 1998; 24: 23–27.

Fakhro AE FB, Al-Asheeri N, Al-Ekri SA. Breast cancer: patient characteristics and survival analysis at Salmaniya Medical Complex, Bahrain. East Mediter Health J 1999; 5: 430–439.

Maalej M FH, Ben Salem S, Daoud J, et al. Breast cancer in Tunisia: clinical and epidemiological study. Bull Cancer 1999; 86: 302–306.

Malik IA. Clinico-pathological features of breast cancer in Pakistan. J Pak Med Assoc 2002; 52: 100–104.

Harirchi I, Ebrahimi M, Zamani N, et al. Breast cancer in Iran: a review of 903 case records. Public Health 2000; 114: 143–145.

Slamon DJ, deKernion JB, Verma IM et al. Expression of cellular oncogenes in human malignancies. Science 1984; 224: 256–262.

Horigushi J, Iino Y, Takei H, et al. Immunohistochemical study on primary and recurrent tumors in patients with local recurrence in the conserved breast. Oncol Rep 2000; 7: 295–298.

Bijker N, Peterse JL, Duchateau L, et al. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 2001; 84: 539–544.

Bankfalvi A, Tory K, Kemper M, et al. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma. Pathol Res Pract 2000; 196: 489–501.

AL-Moundhri M, Nirmala V, AL-Mawali K, et al. Significance of p53, BcI-2, and HER-2/neu protein expression in Omani arab female with breast cancer. Pathol Oncol Res J 2003; 9: 226–231.

el-Ahmady O, el-Salahy E, Mahmoud M, et al. Multivariate analysis of bcl-2, apoptosis, p53 and HER-2/neu in breast cancer: a short-term follow-up. Anticancer Res 2002; 22: 2493–2499.

Temmim L, Baker H, Sinowatz F. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women. Anticancer Res 2001; 21: 743–748.

Shahriari Ahmadi A, Ghavamzadeh A, Amiri N, et al. Clinical, Biological and Pathological Characteristics of Breast Cancer Patients at the Taleghani University Hospital in Kermanshah, Iran. IJHOBMT 2005; 2: 6–11.

Doroudchi M, Talei A, Modjtahedi H, et al. Serum Level of HER-2 Extracellular Domain in Iranian Patients with Breast Cancer: A Follow-up Study. IJI 2005; 2: 191.

Sarmast Shooshtary MH, Talaizadeh AH, Assar S, et al. Evaluation of Carcinoembryonic Antigen CEA and CA15-3 tumor markers in patients operated for breast cancer. Pak J Med Sci 2007; 23: 115–118.

Kermani IA. Variation of tumor markers in 277 breast cancer cases. Asian Pac J Cancer Prev 2004; 5: 291–293

Winer EP, Morro WM, Kent OC, et al. Malignant tumors of the breast. In: Devita Jr VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 6th ed. Philadelphia: Lippincott, Williams & Wilkins; 2001; 1698–1699.

Bland KI, Beenken SW, Copeland EM. The breast. In: Brunicardi FC, Anderson DK, Billjar TR, Dunn DL, Hunter JG, Pollock RE, editors. Schwart’z principles of surgery. 8th ed. New York: McGraw-Hill; 2005; 453–496.

Saphner T, Turmey DC, Gray R. Annual hazard rate of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14: 27–38.

Greenberg PAC, Hortobagyi GN, Smith TL. Longterm follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197.

Pathak KA, Khanna R, Khanna HD, et al. Carcinoembryonic antigen: An invaluable marker for advanced breast cancer. J Postgrad Med 1996; 42: 68–71.

Bottini A, Berruti A, Tampellini M, et al. Influence of neoadjuvant chemotherapy on serum tumor markers CAI5-3, MCA, CEA, TPS and TPA in breast cancer patient with operable disease. Tumour Biol 1997; 18: 301–310.

Arsalan N, Serdar M, Deveci S, et al. Use of CAI5-3, CEA and prolactin for the primary dignosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis. Ann Nucl Med 2000; 14: 395–399.

Meyers WC, Chari RS, Schaffer BK, et al. Neoplasm. In: Townsend Jr CM, Harris JW, editors. Sabiston textbook of surgery. 16th ed. Philadelphia: W.B. Saunders; 2001; 1029–1030.

Nortum LF, Erikstein B, Nustad K. Elevated CA15-3 in breast cancer- Assign of advanced disease. Tumor BioI 2001; 22: 223–228.

Gion M, Barioli P, Mione R, et al. Tumor markers in breast cancer follow-up: A potentially useful parameter still awaiting definitive assessment. Ann Onco1 1995; 6suppl: 31–35.

Fresno M, Molina R, Perez del Rio MJ, et al. P53 expression is of independent predictive value in lymph node-negative breast carcinoma. Eur J Cancer 1997; 33: 1268–1274.

Olayioye MA, Neve RM, Lane HA, et al. The erbB signalling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159–3167.

Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Sem Oncol 2001; 28(suppl 3): 13–19.

Ross JS, Fletcher JA, Linette GP, et al. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8: 307–325.

Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001; 276: 36869–36872.

Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res 2003; 9: 1980–1989

Weihua Z, Andersson S, Cheng G, et al. Update on estrogen signaling. FEBS Lett 2003; 546: 17–24.

Conneely OM, Lydon JP. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids 2000; 65: 571–577.

Molina R, Barak V, Dalen AV, et al. Tumor markers in breast cancer-European group on tumor markers recommendations. Tumor Biol 2005; 26: 281–293.

Duffy MJ. Predictive markers in breast and other cancers. Clin Chem 2005; 51: 494–503.

Fleisher M, Dnistrian AM, Sturgeon CM et al. Practice guidelines and recommendations for use of tumor markers in the clinic. In: Diamandis EP, Fritsche H, Schwartz MK, Chan DW, editors. Tumor Markers, Physiology, Pathobiology, Technology and Clinical Applications, Chicago: AACC Press; 2002: 33–63.

Bast RC, Ravdin P, Hayes DF, et al. American Society of Clinical Oncology Tumor Markers Expert Panel: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865–1878.

Blamey RW. EUSOMA guidelines on endocrine therapy of breast cancer. Eur J Cancer 2002; 38: 615–634.